AlphaGrep UK Ltd grew its stake in shares of Synopsys, Inc. (NASDAQ:SNPS – Free Report) by 296.2% in the third quarter, HoldingsChannel reports. The fund owned 2,060 shares of the semiconductor company’s stock after buying an additional 1,540 shares during the quarter. AlphaGrep UK Ltd’s holdings in Synopsys were worth $896,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of the stock. Elevation Wealth Partners LLC grew its holdings in Synopsys by 96.4% in the second quarter. Elevation Wealth Partners LLC now owns 55 shares of the semiconductor company’s stock valued at $25,000 after purchasing an additional 27 shares during the period. Osbon Capital Management LLC acquired a new position in shares of Synopsys in the 2nd quarter valued at $25,000. IMG Wealth Management Inc. purchased a new stake in shares of Synopsys during the 2nd quarter valued at $28,000. GK Wealth Management LLC purchased a new stake in shares of Synopsys during the 3rd quarter valued at $28,000. Finally, EFG International AG acquired a new stake in shares of Synopsys during the 2nd quarter worth $34,000. 85.47% of the stock is currently owned by hedge funds and other institutional investors.
Key Synopsys News
These are some of the SNPS news items that stood out recently:
- Positive Sentiment: Barclays initiated coverage with an Overweight rating and a $640 price target, citing Synopsys’ leadership in electronic design automation, AI-related R&D tailwinds and long-term free-cash-flow potential. The bullish call was accompanied by a gain in Thursday trading. Barclays starts Synopsys at Overweight
- Positive Sentiment: Synopsys-backed Ansys is supporting an integration between Instem’s toxicology tools and its simulation platform, extending the company’s reach into packaging safety and materials-risk workflows. This could broaden use of its simulation ecosystem, though the financial impact is not specified. Synopsys broadens platform reach
- Negative Sentiment: A valuation analysis argues SNPS may be about 17% overvalued despite improving guidance and business performance, raising questions about whether future cash generation justifies the share price. Synopsys may be overvalued
Insiders Place Their Bets
Wall Street Analyst Weigh In
Several brokerages recently weighed in on SNPS. Roth Capital raised Synopsys to a “buy” rating in a research report on Friday, September 25th. KeyCorp upped their price target on Synopsys from $600.00 to $605.00 and gave the stock an “overweight” rating in a research note on Thursday, October 1st. Sanford C. Bernstein began coverage on Synopsys in a research note on Friday, September 25th. They set an “outperform” rating for the company. Robert W. Baird upgraded Synopsys from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $558.00 to $560.00 in a report on Thursday, August 27th. Finally, Deutsche Bank reaffirmed a “buy” rating and issued a $640.00 price objective (up from $590.00) on shares of Synopsys in a research note on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $577.71.
Get Our Latest Stock Report on SNPS
Synopsys Trading Down 8.0%
NASDAQ SNPS opened at $396.55 on Friday. The company’s fifty day simple moving average is $448.46 and its 200-day simple moving average is $440.14. The stock has a market cap of $76.00 billion, a P/E ratio of 70.06, a PEG ratio of 1.26 and a beta of 1.18. Synopsys, Inc. has a 52 week low of $362.55 and a 52 week high of $539.48. The company has a current ratio of 1.34, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29.
Synopsys (NASDAQ:SNPS – Get Free Report) last released its quarterly earnings results on Wednesday, August 26th. The semiconductor company reported $3.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.67 by $0.24. Synopsys had a net margin of 11.43% and a return on equity of 6.24%. The firm had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.44 billion. During the same quarter in the previous year, the firm posted $3.39 EPS. The firm’s quarterly revenue was up 42.4% on a year-over-year basis. Synopsys has set its Q4 2026 guidance at 4.100-4.160 EPS and its FY 2026 guidance at 15.040-15.100 EPS. Equities research analysts predict that Synopsys, Inc. will post 11.01 EPS for the current fiscal year.
Synopsys announced that its board has initiated a stock repurchase program on Monday, October 5th that allows the company to buy back $1 billion in shares. This buyback authorization allows the semiconductor company to purchase up to 1.1% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its shares are undervalued.
Synopsys Profile
Synopsys, Inc. develops software, semiconductor intellectual property (IP) and services used to design and verify electronic systems. Its electronic design automation (EDA) tools help customers create, simulate, test and validate chips and other complex electronic products, while its IP portfolio provides reusable building blocks for semiconductor designs. The company also offers software security and quality tools that help developers identify vulnerabilities and assess applications throughout the software development process.
Featured Articles
- Five stocks we like better than Synopsys
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding SNPS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Synopsys, Inc. (NASDAQ:SNPS – Free Report).
Receive News & Ratings for Synopsys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synopsys and related companies with MarketBeat.com's FREE daily email newsletter.
